Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial.
about
Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial.Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells.Trisomy 21 consistently activates the interferon response.Low Density Lipoproteins Amplify Cytokine-signaling in Chronic Lymphocytic Leukemia Cells.The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.PPAR-delta modulates membrane cholesterol and cytokine signaling in malignant B cells.
P2860
Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Activity of the Janus kinase i ...... : results of a phase II trial.
@en
Activity of the Janus kinase i ...... : results of a phase II trial.
@nl
type
label
Activity of the Janus kinase i ...... : results of a phase II trial.
@en
Activity of the Janus kinase i ...... : results of a phase II trial.
@nl
prefLabel
Activity of the Janus kinase i ...... : results of a phase II trial.
@en
Activity of the Janus kinase i ...... : results of a phase II trial.
@nl
P2093
P2860
P921
P1433
P1476
Activity of the Janus kinase i ...... : results of a phase II trial.
@en
P2093
David E Spaner
Guizhei Wang
Lindsay McCaw
Mary-Ann Cussen
Patricia Disperati
Yonghong Shi
P2860
P304
P356
10.3324/HAEMATOL.2015.135418
P577
2016-01-27T00:00:00Z